Literature DB >> 18058202

On the rate and extent of drug delivery to the brain.

Margareta Hammarlund-Udenaes1, Markus Fridén, Stina Syvänen, Anubha Gupta.   

Abstract

To define and differentiate relevant aspects of blood-brain barrier transport and distribution in order to aid research methodology in brain drug delivery. Pharmacokinetic parameters relative to the rate and extent of brain drug delivery are described and illustrated with relevant data, with special emphasis on the unbound, pharmacologically active drug molecule. Drug delivery to the brain can be comprehensively described using three parameters: Kp,uu (concentration ratio of unbound drug in brain to blood), CLin (permeability clearance into the brain), and Vu,brain (intra-brain distribution). The permeability of the blood-brain barrier is less relevant to drug action within the CNS than the extent of drug delivery, as most drugs are administered on a continuous (repeated) basis. Kp,uu can differ between CNS-active drugs by a factor of up to 150-fold. This range is much smaller than that for log BB ratios (Kp), which can differ by up to at least 2,000-fold, or for BBB permeabilities, which span an even larger range (up to at least 20,000-fold difference). Methods that measure the three parameters Kp,uu, CLin, and Vu,brain can give clinically valuable estimates of brain drug delivery in early drug discovery programmes.

Entities:  

Mesh:

Year:  2007        PMID: 18058202      PMCID: PMC2469271          DOI: 10.1007/s11095-007-9502-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  116 in total

1.  Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.

Authors:  Stina Syvänen; Rujia Xie; Selma Sahin; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2006-04-07       Impact factor: 4.200

Review 2.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

Authors:  David J Begley
Journal:  Pharmacol Ther       Date:  2004-10       Impact factor: 12.310

3.  Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats.

Authors:  P M Klockowski; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

4.  Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain.

Authors:  P L Golden; G M Pollack
Journal:  Biopharm Drug Dispos       Date:  1998-05       Impact factor: 1.627

5.  Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis.

Authors:  Y Deguchi; K Inabe; K Tomiyasu; K Nozawa; S Yamada; R Kimura
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

6.  Extracellular space of rat cerebral cortex.

Authors:  D L Woodward; D J Reed; D M Woodbury
Journal:  Am J Physiol       Date:  1967-02

7.  Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study.

Authors:  M R Bouw; M Gårdmark; M Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

Review 8.  Multidrug resistance-associated proteins: expression and function in the central nervous system.

Authors:  Shannon Dallas; David S Miller; Reina Bendayan
Journal:  Pharmacol Rev       Date:  2006-06       Impact factor: 25.468

9.  Cerebral perfusion assessment by bolus tracking using hyperpolarized 13C.

Authors:  E Johansson; S Månsson; R Wirestam; J Svensson; J S Petersson; K Golman; F Ståhlberg
Journal:  Magn Reson Med       Date:  2004-03       Impact factor: 4.668

10.  Microwave fixation for the determination of cerebral blood volume in rats.

Authors:  M M Todd; J B Weeks; D S Warner
Journal:  J Cereb Blood Flow Metab       Date:  1993-03       Impact factor: 6.200

View more
  128 in total

1.  Brain microdialysis study of meropenem in two patients with acute brain injury.

Authors:  Claire Dahyot-Fizelier; Ivan Timofeev; Sandrine Marchand; Peter Hutchinson; Bertrand Debaene; David Menon; Olivier Mimoz; Arun Gupta; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

Review 2.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 3.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

4.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

5.  Distribution pattern of mirtazapine and normirtazapine in blood and CSF.

Authors:  Michael Paulzen; Gerhard Gründer; Simone C Tauber; Tanja Veselinovic; Christoph Hiemke; Sarah E Groppe
Journal:  Psychopharmacology (Berl)       Date:  2014-08-23       Impact factor: 4.530

6.  Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.

Authors:  Roger N Gunn; Scott G Summerfield; Cristian A Salinas; Kevin D Read; Qi Guo; Graham E Searle; Christine A Parker; Phil Jeffrey; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-25       Impact factor: 6.200

7.  In vivo Functional Evaluation of Increased Brain Delivery of the Opioid Peptide DAMGO by Glutathione-PEGylated Liposomes.

Authors:  Annika Lindqvist; Jaap Rip; Joan van Kregten; Pieter J Gaillard; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2015-08-15       Impact factor: 4.200

8.  Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid.

Authors:  Mikko Gynther; Aleksanteri Petsalo; Steen H Hansen; Lennart Bunch; Darryl S Pickering
Journal:  Neurochem Res       Date:  2014-12-09       Impact factor: 3.996

9.  Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

Authors:  Aurelija Jucaite; Per Stenkrona; Zsolt Cselényi; Serena De Vita; Nuria Buil-Bruna; Katarina Varnäs; Alicia Savage; Andrea Varrone; Peter Johnström; Magnus Schou; Chris Davison; Andy Sykes; Venkatesh Pilla Reddy; Matthias Hoch; Ana Vazquez-Romero; Mohammad Mahdi Moein; Christer Halldin; Melinda S Merchant; Martin Pass; Lars Farde
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 10.  The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Authors:  Martin E Cooper; Simon E Regnell
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.